AOD-9604 Research Guide

01 What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic, stabilised analogue of the C-terminal fragment of human growth hormone, corresponding to amino acids 176–191 of the 191-amino acid HGH sequence. It was developed by Metabolic Pharmaceuticals in Australia, founded on research by Professor Frank Ng and colleagues who identified that the lipolytic (fat-burning) activity of HGH was concentrated in its C-terminal region, while the anabolic (IGF-1-stimulating, growth-promoting) activity resided in a separate N-terminal domain.

This discovery led to the hypothesis that a fragment corresponding to the lipolytic domain could produce the metabolic benefits of HGH — enhanced fat mobilisation and utilisation — without the adverse effects of full HGH therapy: IGF-1 elevation, insulin resistance, carpal tunnel syndrome, and acromegaly risk at supraphysiological doses.

The 176–191 fragment was further stabilised by the addition of a disulfide bridge, creating AOD-9604 with improved metabolic stability compared to the raw fragment sequence. This stabilised form was taken through clinical trials, obtained FDA GRAS (Generally Recognised As Safe) status, and remains one of the few peptides with meaningful Phase II human clinical data specifically on fat metabolism endpoints.

02 Mechanism of Action

Beta-Adrenergic Stimulation

The primary lipolytic mechanism of AOD-9604 involves stimulation of β3-adrenergic receptors on adipocytes, activating hormone-sensitive lipase (HSL) and triggering the release of stored triglycerides as free fatty acids and glycerol. This is the same receptor pathway stimulated by catecholamines during exercise-induced lipolysis.

Inhibition of Lipogenesis

Beyond promoting fat breakdown, AOD-9604 also inhibits lipogenesis (new fat synthesis) in adipocytes by suppressing the activity of acetyl-CoA carboxylase — a key enzyme in de novo fatty acid synthesis. The dual action (promote breakdown + inhibit synthesis) creates a stronger net lipolytic effect than either mechanism alone.

No GHR / JAK2 / STAT5 Activation

Critically, AOD-9604 does not bind to the growth hormone receptor (GHR) in the classic manner that triggers the JAK2/STAT5 signalling cascade responsible for IGF-1 production, linear growth, and the adverse metabolic effects of HGH excess. This receptor selectivity is the defining pharmacological property of the fragment.

Chondrocyte Stimulation

More recent research has identified AOD-9604's ability to stimulate proteoglycan synthesis in chondrocytes and inhibit matrix metalloproteinase (MMP) activity — enzymes that degrade cartilage extracellular matrix. This entirely separate mechanism underpins the ongoing cartilage/osteoarthritis research interest.

03 Lipolysis Research

AOD-9604's lipolytic properties have been the most extensively studied aspect of its pharmacology, driven by its original development as an anti-obesity drug candidate.

Rodent Obesity Models

In diet-induced obese (DIO) mice, AOD-9604 administered subcutaneously (500 µg/kg/day for 4 weeks) produced significant reductions in total body fat mass, visceral adipose tissue, and plasma free fatty acid levels. The effect was most pronounced in visceral (abdominal) fat — the depot most strongly associated with metabolic disease risk — compared to subcutaneous fat.

Comparison with Full HGH

A key study directly compared AOD-9604 and full HGH at equivalent molar doses in obese mice. Both produced comparable reductions in body fat. However, HGH produced significant insulin resistance and 3.5× higher IGF-1 elevation compared to AOD-9604, which had no effect on insulin sensitivity or IGF-1 levels — demonstrating the clean separation of lipolytic from anabolic/metabolic-adverse effects.

04 No IGF-1 Elevation — Why It Matters

The absence of IGF-1 elevation is AOD-9604's most pharmacologically significant property from a safety and research perspective.

Full HGH therapy at supraphysiological doses causes: insulin resistance (HGH directly antagonises insulin signalling), elevated IGF-1 (anabolic/mitogenic, associated with cancer risk at excess), sodium retention and oedema, joint pain and carpal tunnel syndrome from fluid shifts, and potential acromegalic changes with long-term use. None of these adverse effects have been observed with AOD-9604 in preclinical or clinical studies, because they all require GHR/JAK2/STAT5 activation that AOD-9604 does not produce.

For research models where metabolic confounders are a concern, this makes AOD-9604 a cleaner tool than full HGH or GH secretagogues (GHRP-6, CJC-1295) for studying fat metabolism specifically.

05 Cartilage & Osteoarthritis Research

The cartilage research on AOD-9604 emerged serendipitously from observations of improved joint scores in some early metabolic studies and has developed into a distinct research line.

Proteoglycan Synthesis

In vitro studies with human and bovine chondrocytes demonstrated that AOD-9604 at physiologically relevant concentrations significantly increased proteoglycan synthesis (measured by ³⁵S-sulphate incorporation) and collagen II expression — both markers of cartilage matrix production.

MMP Inhibition

AOD-9604 inhibited MMP-13 and MMP-3 expression in IL-1β-stimulated chondrocytes — cytokine-challenged models simulating the inflammatory environment of osteoarthritis. MMP-13 is the primary collagenase responsible for cartilage breakdown in OA.

In Vivo OA Models

In surgically-induced OA models (medial meniscal transection in rats), AOD-9604 intra-articular injection reduced cartilage degeneration scores, preserved subchondral bone architecture, and reduced synovial inflammation at 8 weeks. A Phase IIa human trial for OA of the knee was initiated by Scinai Immunotherapeutics (Israel) and is ongoing as of 2025.

06 Metabolic Effects

Beyond fat mobilisation, AOD-9604 has shown several secondary metabolic properties in preclinical studies.

Insulin Sensitisation

In insulin-resistant rodent models (high-fat diet), AOD-9604 administration improved glucose tolerance and insulin sensitivity scores, consistent with reduced ectopic fat deposition in liver and muscle. This effect was not seen in euglycaemic animals, suggesting it corrects rather than amplifies insulin signalling.

Non-Alcoholic Fatty Liver (NAFLD)

In diet-induced NAFLD models, AOD-9604 reduced hepatic triglyceride content and improved histological steatosis scores. The mechanism appears to involve both reduced de novo lipogenesis in hepatocytes and enhanced fatty acid oxidation.

Lean Mass Preservation

A consistently observed finding across obesity models is that AOD-9604-mediated fat loss does not reduce lean mass (muscle) — a critical advantage for body composition research models where muscle-sparing is a study endpoint.

07 Clinical Trials Overview

AOD-9604 is among the most clinically-tested research peptides, with a clear regulatory history.

Phase I — Safety

Single and multiple ascending dose studies in healthy volunteers confirmed the safety profile observed in animals. No effect on IGF-1, glucose, insulin, or pituitary hormone levels at doses up to 9,000 µg/day. FDA GRAS designation was subsequently obtained.

Phase II — Obesity

A 12-week, randomised, double-blind, placebo-controlled Phase II trial (n=300) in obese subjects (BMI 30–40) tested oral AOD-9604 at doses of 1,000 µg/day. Results showed statistically significant reduction in body fat (−1.4 kg vs +0.5 kg placebo) with no adverse effects on glucose, IGF-1, or safety markers. The modest absolute effect size reflected the oral delivery route's poor bioavailability.

Phase III — Discontinuation

Phase III trials were initiated but the obesity programme was discontinued when Metabolic Pharmaceuticals was acquired. The data rights were not fully published. This is the primary gap in the AOD-9604 clinical literature.

Osteoarthritis Phase IIa

Ongoing as of 2025 via Scinai Immunotherapeutics; intra-articular injection in knee OA. Results pending.

08 AOD-9604 vs HGH & GH Secretagogues

09 Protocol Notes (Preclinical)

Dosing in Preclinical Studies

• Lipolysis/obesity models: 250–500 µg/kg SC daily (rodents)
• Cartilage/OA models: 30–100 µg intra-articular injection
• Phase II human oral: 1,000 µg/day (note: poor oral bioavailability; parenteral doses are lower)

Administration Routes

• Subcutaneous (SC): Primary systemic route in rodent studies
• Intra-articular: Used for cartilage/OA endpoint studies
• Oral: Used in clinical trials; significant first-pass effect reduces bioavailability

Stability & Reconstitution

Reconstitute in bacteriostatic water or sterile saline. Stable at −20°C for 12+ months lyophilised; use reconstituted solution within 4 weeks at 4°C. The disulfide bridge in AOD-9604 requires avoiding reducing agents (DTT, β-mercaptoethanol) in reconstitution buffer.

10 Frequently Asked Questions